Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Asthma drug omalizumab approved for treatment of urticaria

The monoclonal antibody omalizumab (Xolair) has been approved by the European Commission as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents with inadequate response to H1 antihistamine treatment. Omalizumab is already indicated for severe allergic asthma.

The approved dose for CSU is 300mg given by subcutaneous injection once every four weeks; clinical trial experience beyond six months for this indication is limited. The condition — a persistent, debilitating form of chronic itch, hives and angioedema — is estimated to affect between 318,000 and 630,000 people in the UK at any given time, according to the manufacturer of omalizumab Novartis.

The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended approval of the add-on indication in January 2014.

According to the company, omalizumab is the first and only approved add-on therapy in the UK for CSU patients who have an inadequate response to H1 antihistamine treatment. Novartis claims that up to half of patients do not respond to licensed doses of H1 antihistamines, which, until now, were the only approved treatments for CSU.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11135574

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Pack shot

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.